| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 18th December 2020 | Street Financial S.A. Bay | 1,173,033 | Open or private sale | $18.78 | $22,029,559.74 |
| 2nd December 2020 | Street Financial S.A. Bay | 182,836 | Open or private sale | $18.42 | $3,367,839.12 |
| 19th November 2020 | W Thorpe Mckenzie | 375,000 | Open or private sale | $18.30 | $6,862,500.00 |
| 18th September 2020 | John Simard | 500,000 | Other acquisition or disposition | $0.00 | |
| 15th September 2020 | Sushma Shivaswamy | 20,668 | Exercise of derivative | $7.50 | $155,010.00 |
| 15th September 2020 | Sushma Shivaswamy | 20,668 | Open or private sale | $20.00 | $413,360.00 |
| 10th September 2020 | Sushma Shivaswamy | 19,332 | Open or private sale | $20.01 | $386,833.32 |
| 10th September 2020 | Sushma Shivaswamy | 19,332 | Exercise of derivative | $7.50 | $144,990.00 |
| 1st September 2020 | Queena Han | 27,692 | Exercise of derivative | $4.16 | $115,198.72 |
| 1st September 2020 | Queena Han | 30,000 | Exercise of derivative | $4.24 | $127,200.00 |
X Biotech
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
XBiotech, Inc. is a biopharmaceutical company. Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders.
Ticker: XBIT
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1626878
Employees: 53
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $230 M (0%)
Assets, Current: $258 M (-63%)
Property, Plant and Equipment, Net: $25 M (0%)
Assets: $359 M (-56%)
Accounts Payable, Current: $5 M (143%)
Accrued Liabilities, Current: $5 M (15%)
Liabilities, Current: $14 M (-76%)
Liabilities: $15 M (-75%)
Common Stock, Value, Issued: $246 M (-24%)
Retained Earnings (Accumulated Deficit): $97 M (-77%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $137 Th (29%)
Stockholders' Equity (Parent): $344 M (0%)
Liabilities and Equity: $359 M (-56%)
Cost of Revenue: $13 M (-42%)
Gross Margin: $2 M (-56%)
Research and Development: $3 M (-31%)
General and Administrative Expenses: $6 M (-39%)
Operating Income/Loss: $7 M (-24%)
Other Income, net: $662 Th (-42%)
Provision for income taxes: $332 Th (0%)
